Skip to main content

Vericel Corp

VCEL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000887359

In the last 90 days, Vericel Corp insiders filed 0 open-market purchases and 3 sales; 320 institutions reported holding it in 13F filings for Q2 2026, worth $2.47B in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Vericel Corp changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of VCEL: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders1832180−1
Shares53.1M24952.3M−865.8K (−1.6%)
Value$1.34B$7.00K$1.21B−$125.8M (−9.4%)

2 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (22)

Institutions that held Vericel Corp at the end of Q3 2022 but not at the end of Q2 2022.

Sold out (23)

Institutions that held Vericel Corp at the end of Q2 2022 and filed for Q3 2022 without it.

Not filed for Q3 2022 yet (2)

Institutions that held Vericel Corp at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding VCEL in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Private Capital Group, LLC229$6.00K
Urban Wealth Management, LLC20$1.00K